Literature DB >> 17017868

Challenges in neuronal apoptosis.

Kurt A Jellinger1.   

Abstract

There are myriads of reasons and ways for a neuron to die, among which apoptosis is a specific form that is processed in two major signaling pathways, the TNF-receptor-mediated (extrinsic) and the mitochondria-based (intrinsic) cell death pathway with several avenues of crosstalk between them. The molecular key players of apoptosis, the importance of the Csp cascade via interaction with different death effector domains and the role of the effector Csp-3 driving the execution of the cell death program are reviewed. Recent data suggest that caspases converge amyloid and tau Alzheimer pathologies: beta amyloid peptide activates caspases which on turn cleave tau and via phosphorylation of tau initiate tangle pathology in both Alzheimer disease and other tauopathies. Several mediators show a bifunctional regulation of apoptosis, with both pro- and anti-apoptotic activities. The latter modify the cell death pathway due to inhibition of Csp activation or other protective mechanisms and may delay it or, via abortive apoptosis ("abortosis") lead to prolonged survival of nerve cells. While the role of apoptosis in neurodegeneration is well documented in tissue culture and transgenic animal models, in human postmortem AD brain its occurrence and role are discussed controversially. Given the short duration required for the completion of apoptosis and the chronic progressive course of neurodegeneration in Alzheimer disease and related disorders, the detection of rare neurons displaying morphological signs of apoptosis and expression of the activated key-executing enzyme Csp-3 is realistic, although there is significantly increased incidence of cells with DNA fragmentation, mainly glia, and markers for a "proapoptotic" environment in the aged human brain indicate increased susceptibility of neurons to metabolic and other noxious factors. Postmortem analysis can bridge some but not all of our knowledge gaps, but the results are still controversial, and we need a better understanding of the molecular basis and pathways that drive the yin-yang between neuronal survival and death.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017868     DOI: 10.2174/156720506778249434

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  31 in total

Review 1.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

Review 2.  Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms.

Authors:  S D Crish; D J Calkins
Journal:  Neuroscience       Date:  2010-12-25       Impact factor: 3.590

3.  Effect of hypothalamic proline-rich peptide (PRP-1) on neuronal and bone marrow cell apoptosis.

Authors:  Armen A Galoyan; Josef Krieglstein; Susanne Klumpp; Kristina E Danielian; Karine A Galoian; Wolfram Kremers; Kristina B Bezirganyan; Tigran K Davtyan
Journal:  Neurochem Res       Date:  2007-06-05       Impact factor: 3.996

Review 4.  Neuronal apoptosis revealed by genomic analysis: integrating gene expression profiles with functional information.

Authors:  Sebastiano Cavallaro
Journal:  Neuroinformatics       Date:  2007

5.  Caspase Activation and Caspase-Mediated Cleavage of APP Is Associated with Amyloid β-Protein-Induced Synapse Loss in Alzheimer's Disease.

Authors:  Goonho Park; Hoang S Nhan; Sheue-Houy Tyan; Yusuke Kawakatsu; Carolyn Zhang; Mario Navarro; Edward H Koo
Journal:  Cell Rep       Date:  2020-06-30       Impact factor: 9.423

6.  Mitochondrial dysfunction in NnaD mutant flies and Purkinje cell degeneration mice reveals a role for Nna proteins in neuronal bioenergetics.

Authors:  Lisa Chakrabarti; Rabaab Zahra; Stephen M Jackson; Parsa Kazemi-Esfarjani; Bryce L Sopher; Amanda G Mason; Thomas Toneff; Soyoung Ryu; Scott Shaffer; Janice W Kansy; Jeremiah Eng; Gennifer Merrihew; Michael J MacCoss; Anne Murphy; David R Goodlett; Vivian Hook; Craig L Bennett; Leo J Pallanck; Albert R La Spada
Journal:  Neuron       Date:  2010-06-24       Impact factor: 17.173

Review 7.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

8.  [Not Available].

Authors:  Ryoji Yanashima; Noriyuki Kitagawa; Yoshiya Matsubara; Robert Weatheritt; Kotaro Oka; Shinichi Kikuchi; Masaru Tomita; Shun Ishizaki
Journal:  Front Neuroinform       Date:  2009-05-29       Impact factor: 4.081

9.  Increased accumulation of intraneuronal amyloid beta in HIV-infected patients.

Authors:  Cristian L Achim; Anthony Adame; Wilmar Dumaop; Ian P Everall; Eliezer Masliah
Journal:  J Neuroimmune Pharmacol       Date:  2009-03-17       Impact factor: 4.147

10.  Biological targets for isatin and its analogues: Implications for therapy.

Authors:  Alexei Medvedev; Olga Buneeva; Vivette Glover
Journal:  Biologics       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.